Brief: KDventures' Modus Therapeutics Pauses Enrollment In Phase 2A Study
15/10/2026 06:48
BRIEF-KDventures' Modus Therapeutics Pauses Enrollment In Phase 2A Study Oct 15 (Reuters) - Kdventures AB KDV.ST:
PORTFOLIO COMPANY MODUS THERAPEUTICS TEMPORARILY PAUSES ENROLLMENT IN PHASE 2A STUDY OF SEVUPARIN IN CHRONIC KIDNEY DISEASE WITH ANEMIA
PAUSE IS NOT RESULT OF A REGULATORY DECISION
PAUSE FOLLOWS REPORTING OF SUSAR AFTER SERIOUS ADVERSE EVENT IN SEVUPARIN STUDY
PROOF-OF-CONCEPT READOUT FOR SEVUPARIN STUDY EXPECTED IN Q1 2027
NO ONGOING TREATMENT DISCONTINUED IN SEVUPARIN STUDY AT TIME OF PAUSE
Source text: ID:nMFN47Rp7b
Further company coverage: KDV.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Kdventures AB
See all newsRefile: BRIEF-Umecrine Cognition Gets Notice Of Allowance In US
Brief: KDventures' Modus Therapeutics Pauses Enrollment In Phase 2A Study
Brief: KDventures' AnaCardio Raises €62.5 Million
Brief: Kdventures' Umecrine Cognition Gets Two USPTO Notices Of Allowance For Patent Applications
Brief: Kdventures' Modus Therapeutics Carries Out Directed Issue